Therapeutics: Negative feedback.
Nature Medicine in Cambridge, Massachusetts.
Elie
E
Dolgin
D000339:Affect / Q000187:drug effects / Q000502:physiology; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D004599:Electric Stimulation Therapy; D018698:Glutamic Acid / Q000378:metabolism; D005998:Glycine / Q000378:metabolism; D050487:Glycine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D006240:Happiness; D006801:Humans; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D057181:Pleasure / Q000187:drug effects* / Q000502:physiology; D018967:Risperidone / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D013450:Sulfones / Q000494:pharmacology / Q000627:therapeutic use; D017211:Treatment Failure; D064569:alpha7 Nicotinic Acetylcholine Receptor / Q000819:agonists / Q000378:metabolism
C550631:(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone; D014150:Antipsychotic Agents; D050487:Glycine Plasma Membrane Transport Proteins; D010879:Piperazines; D013450:Sulfones; D064569:alpha7 Nicotinic Acetylcholine Receptor; D018698:Glutamic Acid; D018967:Risperidone; D005998:Glycine